The Future of Bronchiectasis Care: Precision Medicine Ahead

In "The Future of Bronchiectasis Care: Precision Medicine Ahead," the panel closes the series with its outlook on where bronchiectasis care is headed next.

In a closing round, Dr. Basavaraj asks each panelist what excites them most about the future of bronchiectasis care. Dr. Metersky points to two converging trends: increasing incidental diagnosis through imaging obtained for unrelated reasons, and growing general awareness of the disease, both of which should allow earlier intervention before patients become severely symptomatic. He also highlights a robust and diverse therapeutic pipeline, spanning anti-inflammatory agents, novel biofilm-targeting compounds, and monoclonal antibodies directed at bacteria, alongside growing understanding of disease endotypes.

Dr. ElMaraachli emphasizes that the success of DPP1 inhibition validates an entirely new therapeutic strategy: targeting the underlying pathophysiology of bronchiectasis rather than only managing its consequences. He believes this validation has opened the door for the additional anti-inflammatory therapies currently in earlier-phase development. He also highlights a broader shift in clinical thinking, from simply confirming a bronchiectasis diagnosis toward characterizing which endotype a given patient has, moving the field closer to genuinely personalized, precision-based treatment selection.

Dr. Khabbaza says he is encouraged simply by how much more bronchiectasis is discussed across medicine now, crediting recent educational campaigns around brensocatib's launch with raising awareness among providers. He compares the trajectory to asthma and COPD, fields where multiple biologic options eventually allowed clinicians to target specific inflammatory pathways, and expresses hope that treating inflammation earlier, whether eosinophilic or neutrophilic, may ultimately modify long-term disease course.

Dr. ElMaraachli adds that the growing bronchiectasis and NTM care center network represents an important parallel effort to standardize care delivery worldwide. Dr. Metersky closes by noting that brensocatib's approval matters beyond its individual efficacy, since it demonstrates a viable regulatory pathway for bronchiectasis drugs after years of high-profile late-phase failures had discouraged pharmaceutical investment in the space.

Thank you for watching this HCPLive Peer Exchange series on bronchiectasis. Please subscribe to our eNewsletter for information on upcoming video series.